Medindia

X

Drugs from Celgene and Millennium/Johnson & Johnson Will Vie for Dominance in the Multiple Myeloma Drug Market

Monday, November 26, 2007 General News J E 4
Advertisement
WALTHAM, Mass., Nov. 26 Decision Resources, one of theworld's leading research and advisory firms for pharmaceutical and healthcareissues, finds that, through 2016, Celgene's Thalomid and Revlimid andMillennium/Johnson & Johnson's Velcade will vie for dominance in the multiplemyeloma drug market.

The new Pharmacor report entitled Multiple Myeloma finds that, althoughThalomid, Revlimid and Velcade will compete for market leadership, drug-related toxicities and complications suffered by patients with the diseasewill hinder full market penetration by any one agent. The sales of treatmentsfor multiple myeloma exceeded $1 billion in 2006 in the United States, France,Germany, Italy, Spain, the United Kingdom and Japan-a substantial achievementgiven the low incidence of this niche indication.

"The multiple myeloma field is an active area of clinical research, butthere is a distinct lack of mature data currently available for pipelinedrugs," said Clair Gricks, Ph.D., analyst at Decision Resources. "Based onavailable data and expert opinion, we anticipate the launch of five agentsthrough 2016. Additionally, despite recent therapeutic advances, treatingphysicians still consider multiple myeloma to be incurable in the majority ofpatients, and they report that the most significant remaining unmet need isfor drugs that can improve long-term survival outcome."

About Multiple Myeloma

A form of cancer, multiple myeloma affects plasma cells, which are whiteblood cells that produce antibodies for fighting infection. The disease cancause tumors to grow in bones and lead to bone pain and fractures. A dramaticchange is underway in the treatment practice for multiple myeloma as old stylechemotherapy regimens are being abandoned in favor of recently approvedimmunomodulatory drugs and proteasome inhibitors. Although long-term survivaldata for these treatments are presently lacking, results so far show animproved efficacy for patients. However, such agents command a premium price,resulting in substantial reimbursement issues and cost constraints across allof the markets under study in this report.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in marketresearch publications, advisory services, and consulting designed to helpclients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com

SOURCE Decision Resources
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Tengion to Present at Piper Jaffray 19th Annual He...
S
JODIE FOSTER TO PRESENT THE TREVOR PROJECT FOUNDER...